

PATENT
454313-2340.2**IN THE CLAIMS**

Please amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Sub 1
C1
1. (Twice amended) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused myocarditis, and/or abortion and/or intrauterine infection in a population of pigs comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes a PCV-2 polypeptide.

2. (Twice amended) A composition for eliciting an immune response and thereby reducing PCV-2-caused myocarditis and/or abortion and/or intrauterine infection associated with PCV-2 comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes a PCV-2 antigen.

C2
21. (Twice amended) The composition of claims 1 or 2, additionally including at least one immunogen from at least one additional pig pathogen, or a vector expressing such an immunogen, wherein the vector, the at least one immunogen from at least one additional pig pathogen can also be the vector expressing the PCV-2 polypeptide or antigen.

31. (Twice amended) A method for minimizing the symptoms of porcine circovirus-2 (PCV-2)-caused myocarditis, and/or abortion and/or intrauterine infection in a population of pigs comprising inducing an immunological or immunogenic response against PCV-2 in the population of pigs comprising administering to the population of pigs the composition of claim

C3
1.

32. (Twice amended) A method for minimizing the symptoms of PCV-2-caused myocarditis and/or abortion and/or intrauterine infection in a population of pigs comprising inducing an immunological or immunogenic response against PCV-2 in the population of pigs comprising administering to the population of pigs the composition of claim 2.

Sub 4
C4
50. (Twice amended) The method of claim 31, additionally including at least one immunogen from at least one additional pig pathogen, or a vector expressing such an immunogen, wherein the vector, the at least one immunogen from at least one additional pig pathogen, can also be the vector expressing the PCV-2 polypeptide.

PATENT
454313-2340.2

51. (Twice amended) The method of claim 32, additionally including at least one immunogen from at least one additional pig pathogen, or a vector expressing such an immunogen, wherein the vector, the at least one immunogen from at least one additional pig pathogen, can also be the vector expressing the PCV-2 antigen.

60. (Twice amended) The method of claims 31 or 32, wherein the polypeptide or antigen is recombinantly produced.

62. (Amended) The method of claims 31 or 32, wherein the administering is prior to breeding.

63. (Amended) The method of claims 31 or 32, wherein the population includes one or more pregnant female pigs and the administering is during pregnancy of the one or more female pigs.

82. (Amended) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused myocarditis comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes a PCV-2 polypeptide.

83. (Amended) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused abortion comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes a PCV-2 polypeptide.

84. (Amended) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused intrauterine infection comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes a PCV-2 polypeptide.

85. (Amended) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused myocarditis comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes a PCV-2 antigen.

PATENT
454313-2340.2

86. (Amended) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused abortion comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector expressing and containing and expressing nucleotide sequence, wherein the nucleotide sequence encodes a PCV-2 antigen.

87. (Amended) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused intrauterine infection comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes a PCV-2 antigen.

88. (Amended) A method for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused myocarditis comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 1, 2 or 94.

89. (Amended) A method for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused abortion comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 1, 2 or 94.

90. (Amended) A method for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused intrauterine infection comprising inducing an immunological or immunogenic response against PCV-2 in a pig comprising administering to the pig the composition of claim 1, 2 or 94.

Please add the following claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

--94. (New) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused myocarditis, and/or abortion and/or intrauterine infection in a population of pigs comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes a PCV-2 epitope which is specific to PCV-2 and not specific to PCV-1.

PATENT
454313-2340.2

95. (New) The composition of claim 94, wherein the vector comprises a DNA vector plasmid, a *E. coli*, a baculovirus, a pig herpes viruses, including Aujeszky's disease virus, a porcine adenovirus, or a poxvirus, including a vaccinia virus, an avipox virus, a canarypox virus, or a swinepox virus.

96. (New) The composition of claim 95, wherein the vector is a DNA vector.

97. (New) The composition of claim 95, wherein the vector is a canarypox virus.

98. (New) A method for minimizing the symptoms of porcine circovirus-2 (PCV-2)-caused myocarditis, and/or abortion and/or intrauterine infection in a population of pigs comprising inducing an immunological or immunogenic response against PCV-2 in the population of pigs comprising administering to the population of pigs the composition of claim 94.

99. (New) The method of claim 98, wherein the vector comprises a DNA vector plasmid, a *E. coli*, a baculovirus, a pig herpes viruses, including Aujeszky's disease virus, a porcine adenovirus, or a poxvirus, including a vaccinia virus, an avipox virus, a canarypox virus, or a swinepox virus.

100. (New) The method of claim 99, wherein the vector is a DNA vector.

101. (New) The method of claim 99, wherein the vector is a canarypox virus.

102. (New) The method of claim 98, wherein the polypeptide or antigen is recombinantly produced.

103. (New) The method of claim 98, wherein the administering is prior to breeding.

104. (New) The method of claim 98, wherein the population includes one or more pregnant female pigs and the administering is during pregnancy of the one or more pregnant female pigs.

105. (New) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused myocarditis comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes an epitope which is specific to PCV-2 and not specific to PCV-1.

106. (New) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused abortion comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing

PATENT
454313-2340.2

an exogenous nucleotide sequence, wherein the nucleotide sequence encodes an epitope which is specific to PCV-2 and not specific to PCV-1.

C7 107. (New) A composition for eliciting an immune response and thereby reducing porcine circovirus-2 (PCV-2)-caused intrauterine infection comprising a pharmaceutically or veterinarily or medically acceptable carrier and an active agent comprising a vector containing and expressing an exogenous nucleotide sequence, wherein the nucleotide sequence encodes an epitope which is specific to PCV-2 and not specific to PCV-1.--

Please cancel claims ~~61, 64, and 91-93~~ without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.